Kevin Walton runs a company built on a simple, uncomfortable observation: most drugs aim at a single target, and most of the diseases that matter most do not have one. As Chief Executive Officer and Board Director of Baseimmune, the London biotech he took over in 2024, his job is to turn that gap into medicine.
Baseimmune designs antigens - the pieces that teach the immune system what to attack - using artificial intelligence and computational protein design. Where a conventional vaccine picks one component of a pathogen and hopes it holds, Baseimmune's platform sifts genomic, proteomic and immunological data to assemble synthetic antigens that engage many points at once. The pitch, in the company's early years, was future-proof vaccines: shots that could keep up with a mutating virus rather than chasing it. Under Walton, the same idea is being pushed somewhere harder.
In March 2026, Baseimmune announced a strategic expansion into fibrosis, a class of scarring diseases where organs quietly stiffen and fail. Its lead program targets idiopathic pulmonary fibrosis, or IPF, a lung condition where the handful of approved therapies only slow the decline. It is a deliberate move away from the company's original comfort zone of infectious disease, and a direct test of Walton's central thesis.
"Fibrosis is a biologically complex, organ-specific disease process that has consistently challenged single-target drug development."
The logic is that if a disease is driven by many pathways working together, a drug that blocks just one will always be outflanked. Baseimmune's answer is to use computation to design molecules that hit several pro-fibrotic pathways simultaneously - the same multi-target instinct that shaped its vaccine work, now pointed at chronic illness. Proof-of-concept efficacy readouts are expected across 2026 and 2027. If they land, they will validate not just a program but a way of building medicines.
01 / THE OPERATORA dealmaker takes the wheel
Walton did not come up through the lab bench. He came up through the deal side of biotech - the part of the industry that decides what gets bought, licensed, partnered and funded. Before Baseimmune he was Senior Director of Corporate Development at Moderna, the company that turned mRNA from a research curiosity into a household word. Before that he held corporate and business development roles at StrideBio, Curis and G1 Therapeutics, where his titles ranged from Senior Manager of Business Development to Chief of Staff to Director of Corporate Development and Strategy.
Further back, his career reads like a tour of the machinery behind the medicine: finance and strategy work at Amgen and Eli Lilly, pharmaceutical M&A and licensing analysis at Torreya Partners, and consulting at CRA International. It is an unusual resume for a biotech CEO - heavy on capital, strategy and negotiation rather than pipettes - and it says something about what Baseimmune decided it needed at this stage. A company with strong science, born inside a university, often struggles with the next problem: becoming a business that can raise money, strike partnerships and survive contact with regulators.
02 / THE INHERITANCEA science story he did not write
Baseimmune was not Walton's idea. It was founded in 2019 by three scientists - Joshua Blight, Ariane Gomes and Phillip Kemlo - who met during their PhDs at the University of Oxford's Jenner Institute, one of the world's leading vaccine research centers. Their method, the company likes to note, produced a vaccine that reached clinical trials faster than any in the institute's history. That pedigree drew early backers, a seed round, and eventually a Series A supported by investors including MSD's Global Health Innovation Fund, Hoxton Ventures and IQ Capital.
Handing a founder-built company to a professional CEO is one of the most fraught transitions in startups, and often decides whether a breakthrough becomes a product or a footnote. Walton's task is that handoff in real time: keeping the scientific ambition intact while adding the commercial discipline that turns a platform into a pipeline. The founders remain central - Blight and Kemlo sit on the board alongside Walton - but the strategic direction, the move into chronic disease, and the pitch to the market now run through him.
03 / THE CREDENTIALSLaw, business, and a bet on biology
Walton's training is as much boardroom as laboratory. He holds a Juris Doctor, earned magna cum laude, from Duke University School of Law, and an MBA from Duke's Fuqua School of Business, where he was named a Fuqua Scholar. His undergraduate degree, in economics and history, is from Boston College. It is the toolkit of someone built to structure deals, read contracts and weigh risk - now applied to a company whose core product is designed by an algorithm and tested in biology that no contract can guarantee.
Four academic credentials - including a law degree and an MBA - leading a company whose medicine is designed by software.
A US-based executive running a UK biotech: Walton works from the Boston area while Baseimmune's labs sit in London.
Baseimmune's original pipeline read like a global-health map - malaria, coronavirus and African swine fever.
04 / THE BETWhat success would prove
The stakes for Walton go beyond one company. AI in biotech has produced an abundance of slide decks and a shortage of approved drugs. The hard part is never the model; it is the pipeline, the trials, the readouts and the years of biology that refuse to cooperate. By pointing Baseimmune's computational platform at fibrosis - a category littered with expensive failures - Walton is choosing a difficult proving ground on purpose. A single-target drug can only slow IPF. If a computationally designed, multi-pathway approach can do better, it would be evidence that the method travels beyond vaccines and into the diseases that have resisted everything else.
For now, Walton occupies the seat where scientific ambition meets commercial reality. He inherited a breakthrough and a team that had already done the impossible once, at Oxford. The question he is paid to answer is whether it can be done again - this time as a company, and this time against biology that does not forgive a single point of attack.